What is Sooma?
Sooma Medical is at the forefront of developing and distributing innovative brain stimulation treatments, primarily focusing on transcranial direct current stimulation (tDCS) for depression and chronic pain. Their flagship product, Sooma tDCS, offers a noninvasive and drug-free alternative for healthcare professionals seeking effective symptom relief and improved patient care efficiency. The company has established a significant international presence, with its treatment being prescribed in over 35 countries, making it the most widely adopted tDCS solution globally. This widespread adoption is supported by robust clinical studies and positive patient outcomes, reinforcing Sooma's commitment to advancing mental health and pain management through accessible technology.
How much funding has Sooma raised?
Sooma has raised a total of $6.9M across 2 funding rounds:
Unspecified
$1.4M
Other Financing Round
$5.5M
Unspecified (2019): $1.4M with participation from Business Finland
Other Financing Round (2024): $5.5M led by Voima Ventures
Key Investors in Sooma
Voima Ventures
Voima Ventures is a venture capital firm focused on funding leading scientific deep tech ventures in the Nordics and Baltics. They specialize in supporting science-driven innovation and entrepreneurial expertise to address significant global challenges, investing from pre-seed to series B stages.
Business Finland
Business Finland is a Finnish government agency that provides funding and internationalization services for technology companies. They support innovation and growth for Finnish businesses, aiming to enhance their competitiveness in the global market.
What's next for Sooma?
With the recent major strategic investment and a substantial total funding amount of $6.9M, Sooma is poised for accelerated growth and market penetration. The company's focus on expanding its global footprint and enhancing its innovative brain stimulation technology suggests a strategic push towards scaling operations and further clinical validation. Future developments are likely to involve broader market access, potential new product applications, and continued research to solidify its leadership in noninvasive neuromodulation therapies. This funding round, characterized as enterprise-level, indicates Sooma is likely in a scaling or expansion phase, aiming to solidify its market dominance and explore new therapeutic avenues.
See full Sooma company page
